Anti-hPD1-Pem-hIgG2

Human PD-1 (pembrolizumab) antibody - Human IgG2

ABOUT

Human PD-1 (pembrolizumab) antibody - Human IgG2

Anti-hPD1-Pem-hIgG2 features the constant region of the human IgG2 isotype and the variable region of pembrolizumab. Pembrolizumab is a humanized IgG4 monoclonal antibody that contains an engineered hinge region mutation (S228P) designed to prevent exchange of IgG4 molecules. This antibody targets the PD-1 receptor found on activated T cells, B cells, and myeloid cells. Under normal physiological conditions, PD-1 negatively regulates T cell activation thereby preventing autoimmunity [1]. Under pathological conditions, cancer cells produce PD-L1 (programmed cell death 1 ligand 1), the agonist that binds and activates PD-1. Activated PD-1 enables the cancer cells to evade the immune system. Pembrolizumab binds and blocks the activation of the PD-1 receptor, thereby resulting in the activation of T cells [2]. Pembrolizumab has been approved by the FDA for the treatment of metastatic malignant melanoma, and is currently under regulatory review in the EU [3].

Human IgG2 is the second most common antibody present in serum. This isotype is resistant to cleavage by proteolytic enzymes, due to a short hinge region. Human IgG2 displays low complement-dependent cytotoxicity (CDC) and very low antibody-dependent cell-mediated cytotoxicity (ADCC).

Anti-hPD1-Pem-hIgG2 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography.

 

References:

1. McDermott D. & Atkins M. 2013. PD-1 as a potential target in cancer therapy. Cancer Med. 2(5): 662–673.
2. Tumeh PC. et al., 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515(7528):568-71.
3. Poole RM., 2014. Pembrolizumab: first global approval. Drugs. 4(16):1973-81.

All products are for research use only, and not for human or veterinary use.

SPECIFICATIONS

Specifications

Target

Programmed cell death 1 (PD-1) receptor

Target species

Human

Applications

Anti-hPD1-Pem-hIgG2 binds and blocks ligand activation of the PD-1 receptor found on the surface of activated T cells.

Isotype
hIgG2
kappa
Source
CHO cells
Purification
Protein G
Formulation buffer

0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose and stabilizing agents.

Preservative
Azide-free
Aggregation

< 5%

Reconstitution buffer
Sterile water
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

Flow cytometry

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hPD1-Pem-hIgG2
  • Cat code: 
    hpd1pe-mab2
  • Quantity: 
    Custom size

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20°C
    Stability: Reconstituted antibody is stable for 1 month when stored at 4°C and for 1 year when aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

    Caution:

    • Avoid repeated freeze-thaw cycles

DOCUMENTS

Documents

Anti-hPD1-Pem-hIgG2

Technical Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?